Award-winning scientist Professor Jens Juul Holst, alongside co-authors Professor Sten Madsbad, Professor Jens Meldgaard Bruun, and Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen, trace the scientific breakthroughs and clinical advances that have made GLP-1 therapies, such as Ozempic and Wegovy, essential tools for improving blood sugar control and promoting meaningful, lasting weight loss in patients worldwide
Studies have demonstrated that GLP-1s can help people with obesity lose as much as 15% of their body weight
The choice between tablets and injections depends on personal preference, tolerance, and how well the oral formulation works for each individual patient
However, everyone responds differently to these medications
However, no single food dramatically increases GLP-1 or works the same way as prescription GLP-1 medications
Contrast that with the sometimes overly dramatic effects offered by a facelift